CA2548585A1 - Treatment of viral infections - Google Patents

Treatment of viral infections Download PDF

Info

Publication number
CA2548585A1
CA2548585A1 CA002548585A CA2548585A CA2548585A1 CA 2548585 A1 CA2548585 A1 CA 2548585A1 CA 002548585 A CA002548585 A CA 002548585A CA 2548585 A CA2548585 A CA 2548585A CA 2548585 A1 CA2548585 A1 CA 2548585A1
Authority
CA
Canada
Prior art keywords
seq
derivative
polypeptide
analogue
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002548585A
Other languages
English (en)
French (fr)
Inventor
Curtis Dobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ai2 Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2548585A1 publication Critical patent/CA2548585A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CA002548585A 2003-12-17 2004-12-17 Treatment of viral infections Abandoned CA2548585A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0329254.7A GB0329254D0 (en) 2003-12-17 2003-12-17 Treatment of viral infections
GB0329254.7 2003-12-17
PCT/GB2004/005360 WO2005058959A2 (en) 2003-12-17 2004-12-17 Treatment of viral infections

Publications (1)

Publication Number Publication Date
CA2548585A1 true CA2548585A1 (en) 2005-06-30

Family

ID=30471239

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002548585A Abandoned CA2548585A1 (en) 2003-12-17 2004-12-17 Treatment of viral infections

Country Status (11)

Country Link
US (3) US7691382B2 (enExample)
EP (2) EP1709075B9 (enExample)
JP (2) JP2007535910A (enExample)
CN (2) CN1894281B (enExample)
AU (1) AU2004299343B8 (enExample)
CA (1) CA2548585A1 (enExample)
DK (1) DK1709075T3 (enExample)
ES (1) ES2389078T3 (enExample)
GB (1) GB0329254D0 (enExample)
PL (1) PL1709075T3 (enExample)
WO (1) WO2005058959A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329254D0 (en) * 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections
GB0329958D0 (en) 2003-12-24 2004-01-28 Univ Manchester Treatment of viral infections
GB0404374D0 (en) * 2004-02-27 2004-03-31 Univ Manchester Treatment of bacterial infections
GB0513096D0 (en) * 2005-06-28 2005-08-03 Strathclyde Treatment of microbial infections
EP1937815B1 (en) * 2005-09-13 2015-05-13 National Research Council of Canada Methods and compositions for modulating tumor cell activity
EP2085774B1 (en) * 2008-02-01 2018-04-11 Kraft Foods R & D, Inc. Method for determining the texture of food material
WO2009102715A2 (en) * 2008-02-11 2009-08-20 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Peptide therapy for ocular herpes infections
US8618247B2 (en) * 2008-02-14 2013-12-31 Enplas Corporation Peptide, use of the peptide, method for the production of the peptide, solid support having the peptide immobilized thereon, and method for production of the solid support
PT2504363T (pt) 2009-11-24 2019-08-02 Nat Res Council Canada Anticorpos anticlusterina e fragmentos de ligação ao antigénio e a sua utilização para reduzir o volume de um tumor
US20120053128A1 (en) * 2010-08-26 2012-03-01 Xavier University Method of inhibiting angiogenesis
WO2013013187A1 (en) 2011-07-21 2013-01-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Apolipoprotein e polypeptides and their use
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
WO2013148305A1 (en) * 2012-03-29 2013-10-03 Xavier University Of Louisiana Method for treating diabetic retinopathy
WO2016054250A1 (en) * 2014-10-01 2016-04-07 Cascadia Life Sciences Llc Anti-viral peptides
WO2016054310A1 (en) 2014-10-01 2016-04-07 Plant Health Care, Inc. Hypersensitive response elicitor peptides and use thereof
JP2017532981A (ja) 2014-10-01 2017-11-09 プラント ヘルス ケア インコーポレイテッド 破壊された過敏感反応ボックスを有するエリシターペプチド及びその使用
WO2017176588A1 (en) 2016-04-06 2017-10-12 Plant Health Care, Inc. Beneficial microbes for delivery of effector peptides or proteins and use thereof
ES3039620T3 (en) 2016-04-06 2025-10-23 Plant Health Care Inc Hypersensitive response elicitor-derived peptides and use thereof
WO2020223581A1 (en) * 2019-04-30 2020-11-05 Maxwell Biosciences, Inc. Halogenated antimicrobial peptoids
CN116813712B (zh) * 2023-06-16 2024-03-29 东北农业大学 一种富含Trp的α-螺旋结构抗菌肽W33及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5473039A (en) * 1989-08-18 1995-12-05 The Scripps Research Institute Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs
WO1993000443A1 (en) * 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
US5344822A (en) 1992-08-12 1994-09-06 The Rogosin Institute Methods useful in endotoxin prophylaxis and therapy
JP2001518449A (ja) * 1997-09-30 2001-10-16 デューク・ユニバーシティー アポリポタンパク質ｅ／成長因子複合体およびその使用法
US7205280B2 (en) * 1998-03-11 2007-04-17 Cognosci, Inc. Methods of suppressing microglial activation
GB0200757D0 (en) * 2002-01-15 2002-02-27 Univ Manchester Diagnostic methods
GB0329254D0 (en) * 2003-12-17 2004-01-21 Univ Manchester Treatment of viral infections

Also Published As

Publication number Publication date
JP2007535910A (ja) 2007-12-13
AU2004299343B2 (en) 2011-03-10
CN1894281A (zh) 2007-01-10
AU2004299343B8 (en) 2012-02-23
EP1709075A2 (en) 2006-10-11
CN1894281B (zh) 2012-10-03
US20070117746A1 (en) 2007-05-24
JP2012115277A (ja) 2012-06-21
EP1709075B9 (en) 2012-10-24
US20130150288A1 (en) 2013-06-13
US7691382B2 (en) 2010-04-06
EP1709075B1 (en) 2012-06-06
PL1709075T3 (pl) 2012-11-30
DK1709075T3 (da) 2012-08-27
WO2005058959A2 (en) 2005-06-30
AU2004299343A1 (en) 2005-06-30
US20100221273A1 (en) 2010-09-02
GB0329254D0 (en) 2004-01-21
ES2389078T3 (es) 2012-10-23
WO2005058959A3 (en) 2005-12-15
CN102336815A (zh) 2012-02-01
EP2277911A1 (en) 2011-01-26

Similar Documents

Publication Publication Date Title
US20130150288A1 (en) Treatment of viral infections
CN114736272B (zh) 一种优化病毒膜融合抑制剂的方法及广谱抗冠状病毒脂肽和应用
Owens et al. Apolipoprotein AI and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation.
Zeng et al. Histidine-rich modification of a scorpion-derived peptide improves bioavailability and inhibitory activity against HSV-1
WO2013167299A1 (en) Anti-inflammatory peptides and composition comprising the same
US5441936A (en) Antiviral peptides
EP1711526B1 (en) Treatment of viral infections
CN111643656A (zh) 广谱冠状病毒膜融合抑制剂及其抗艾滋病病毒的应用
CN110248953A (zh) 新型订书肽及其用途
WO2009155789A1 (zh) 抑制hiv感染的多肽及其衍生物
WO2009095500A1 (en) Inhibitors of lentiviral replication
EP4293037A1 (en) Artificial small molecule interfering peptide of dapk1 phosphorylated substrate and pharmaceutical use thereof
HK1151185A (en) Treatment of viral infections apo e
EP2538961B1 (en) Inhibition of necrosis
Vangelista et al. Critical role of the N-loop and β1-strand hydrophobic clusters of RANTES-derived peptides in anti-HIV activity
EP2225272A2 (en) Novel peptides derived from ncam (fgls)
CN100455594C (zh) 抑制hiv病毒融合的多肽及其用途
WO2013075594A1 (zh) 人工设计的抗hiv感染多肽、组合物以及用途
KR100438415B1 (ko) 헬리코박터 파일로리 유래의 신규한 항바이러스 펩타이드및 그의 용도
Woo et al. Characterization of Rhodamine Conjugated Agiotensin II Peptide: Synthesis, Analysis and Receptor Binding and Internalization.
US20060258565A1 (en) Methods of inhibiting viral infection
WO2012101617A1 (en) Antiviral peptides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150630

FZDE Discontinued

Effective date: 20150630